北京时间2025年1月17日,生物制药公司ARS Pharmaceuticals Inc.(SPRY)股价盘中出现大涨,截至收盘,股价上涨6.49%,引发市场广泛关注。
据分析,雷蒙德詹姆斯公司在当天发布研报,维持ARS Pharmaceuticals的评级为"强烈买入",并将目标价从26美元上调至28美元。分析师对该公司新型肾上腺素喷雾剂Neffy的前景持乐观态度,认为它能够有效治疗过敏反应,市场潜力巨大。
ARS Pharmaceuticals是一家专注于开发新型治疗过敏药物的生物技术公司。其旗舰产品Neffy是一种吸收增强型肾上腺素鼻喷雾剂,具有给药快速、携带方便等优势,有望成为替代肾上腺素注射的新型治疗方式。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.